Showing results (441-450 of 472) with videos related to

Sort By:
Pageof 48
The Journal of Urology|December 2, 2024
Validation of Prognostic Models for Renal Cell Carcinoma Recurrence, Cancer-Specific Mortality, and All-Cause MortalityAnita Robert, Ranjeeta Mallick, Daniel I McIsaac, et al.
JAMA Network Open|June 10, 2022
Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell CarcinomaVishal Navani, Matthew Ernst, J Connor Wells, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trialGeorg A Bjarnason, Jennifer J Knox, Christian K Kollmannsberger, et al.
BJU International|December 4, 2024
Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?Mustafa Soytas, Alice Dragomir, Ghady Bou-Nehme Sawaya, et al.
Addiction Science & Clinical Practice|July 26, 2024
Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorderChristopher S Freet, Brianna Evans, Timothy R Brick, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 4, 2020
Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer populationCamilla Tajzler, Simon Tanguay, Ranjeeta Mallick, et al.
JCI Insight|March 15, 2021
A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2Abdelilah Majdoubi, Christina Michalski, Sarah E O'Connell, et al.
Clinical Genitourinary Cancer|May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
Scientific Reports|May 20, 2021
A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cellsKatherine E Harris, Kyle J Lorentsen, Harbani K Malik-Chaudhry, et al.
Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219Barbara Melosky, Penelope Bradbury, Dongsheng Tu, et al.
Pageof 48